PriceTargets.com logo

Cyclerion Therapeutics - CYCN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.58 As of 11/15/2024 01:00 AM ET
▲ +0.81 (45.76%)

This chart shows the closing price for CYCN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cyclerion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYCN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYCN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cyclerion Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.58.

This chart shows the closing price for CYCN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cyclerion Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/20/2021Truist FinancialInitiated CoverageBuy$280.00
9/24/2021Cantor FitzgeraldInitiated CoverageOverweight$140.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Cyclerion Therapeutics logo
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $2.58
Low: $1.76
High: $3.00

50 Day Range

MA: $2.69
Low: $1.77
High: $3.16

52 Week Range

Now: $2.58
Low: $1.71
High: $5.25

Volume

11,988,990 shs

Average Volume

40,031 shs

Market Capitalization

$6.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Cyclerion Therapeutics?

The following Wall Street analysts have issued reports on Cyclerion Therapeutics in the last twelve months:
View the latest analyst ratings for CYCN.

What is the current price target for Cyclerion Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cyclerion Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cyclerion Therapeutics in the next year.
View the latest price targets for CYCN.

What is the current consensus analyst rating for Cyclerion Therapeutics?

Cyclerion Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CYCN.

What other companies compete with Cyclerion Therapeutics?

Other companies that are similar to Cyclerion Therapeutics include Orgenesis, ObsEva, Chembio Diagnostics, Marinus Pharmaceuticals and Cadrenal Therapeutics. Learn More about companies similar to Cyclerion Therapeutics.

How do I contact Cyclerion Therapeutics' investor relations team?

Cyclerion Therapeutics' physical mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company's listed phone number is (857) 327-8778 and its investor relations email address is [email protected]. The official website for Cyclerion Therapeutics is www.cyclerion.com. Learn More about contacing Cyclerion Therapeutics investor relations.